Midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (GNPs) with a core focus on therapeutics for diabetes and cancer.
Midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. In 2012, Midatech established MidaSol Therapeutics LP, a strategic joint venture with MonoSol Rx LLC to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. MidaSol’s lead product, Midaform™ Insulin PharmFilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter Phase II clinical studies in 2014. These technologies are also being evaluated in the diabetes area by a major US pharmaceutical company.
Midatech’s unique GNP technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. Multiple drug molecules can be attached to one of its GNPs allowing multivalent drug or multi-drug delivery. The size of the GNPs potentially also enables drug delivery via a variety of different routes of administration, such as oral, parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation.
Midatech has exclusive world-wide IP for the technology covering design, manufacture and application of nanoparticles in therapeutic and diagnostic pharmaceutical areas as well as in other industries.
In 2014, Midatech Pharma acquired Q Chip, now Midatech Pharma Wales to support novel delivery platforms and product developments in cancer, diabetes and ophthalmology. Q Chip has developed a complementary technology and products that allow sustained release of substances over extended periods of time and will provide a platform to incorporate Midatech's gold nanoparticle (GNP) compounds for sustained and extended release.

Show more
Type
Public
HQ
Milton, GB
Founded
2000
Size (employees)
84 (est)+14%
Midatech Pharma was founded in 2000 and is headquartered in Milton, GB
Report incorrect company information

Key People/Management at Midatech Pharma

Nick Robbins-Cherry

Nick Robbins-Cherry

Chief Financial Officer
Daniel Palmer

Daniel Palmer

Chief Scientific Officer
Tom Coulter

Tom Coulter

Head of Chemistry
David Webb

David Webb

VP Manufacturing
Emma Matthews

Emma Matthews

Executive PA and HR Manager

Midatech Pharma Office Locations

Midatech Pharma has an office in Milton
Milton, GB (HQ)
65 Innovation Drive Milton Park Abingdon Oxfordshire
Show all (1)
Report incorrect company information

Midatech Pharma Financials and Metrics

Midatech Pharma Financials

Midatech Pharma's revenue was reported to be £6.92 m in FY, 2016 which is a 403.5% increase from the previous period.
GBP

Revenue (FY, 2016)

6.9 m

Revenue growth (FY, 2015 - FY, 2016), %

403.5%

Gross profit (FY, 2016)

6.3 m

Gross profit margin (FY, 2016), %

90.4%

Net income (FY, 2016)

(20.2 m)

Cash (31-Dec-2016)

17.6 m
GBPFY, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2016

Revenue

147 k147 k157 k1.4 m6.9 m6.9 m

Revenue growth, %

7%776%403%403%

Cost of goods sold

70 k667 k667 k

Gross profit

1.3 m6.3 m6.3 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.4 m30.3 m16.2 m17.6 m

Accounts Receivable

160 k189 k985 k1.4 m

Inventories

459 k817 k

Current Assets

4.1 m31.6 m20.3 m22.3 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.1 m)(8.8 m)(10.1 m)(20.2 m)

Cash From Operating Activities

(4.4 m)(5.5 m)(12.4 m)(13.1 m)

Cash From Financing Activities

6.7 m34.3 m(219 k)15.3 m

Net Change in Cash

2.3 m27.9 m(14.2 m)967 k
GBPY, 2016

Financial Leverage

1.2 x
Show all financial metrics

Midatech Pharma Operating Metrics

Midatech Pharma's Patent Applications was reported to be 81 in Apr, 2017.
Apr, 2017

Patent Applications

81

Patents Issued

77

Patents and Patent Applications

35
Show all operating metrics
Report incorrect company information